Behavioral Finance
May 17, 2026
Board meeting frequency is the cheapest forensic governance signal hidden in every Indian annual report. SEBI LODR Reg 17(2) sets the floor at 4, best-practice boards meet 8-12 times, and Titan Biotech FY25 illustrates the disciplined end with 14 meetings sitting alongside a fortress balance sheet.
May 16, 2026
Myopic Loss Aversion — Benartzi & Thaler's 1995 Nobel-grade explanation of the equity premium puzzle, applied to Indian retail investors, with Titan Biotech FY25 audited numbers as an anti-MLA corporate-cadence case study.
May 16, 2026
Net Debt to EBITDA is the single ratio professional credit analysts use most when assessing survival odds. This educational deep-dive teaches how to read it, where retail investors misinterpret it, and how Titan Biotech (BSE: 524717) FY25 audited numbers illustrate a -0.75x net-cash fortress reading. Not a buy/sell recommendation.
May 16, 2026
Warren Buffett's 1990 Berkshire letter introduced look-through earnings — dividends plus your proportional share of retained profits. Why this single number reveals what your portfolio truly earned, illustrated by Titan Biotech FY25's high-retention, low-debt capex discipline.
